Chlorambucil is a cytotoxic chemotherapy drug, prescribed for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and lymphosarcoma. The risk or severity of adverse effects can be ...

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax ...

Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database A total of 100 ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic lymphocytic leukemia treated with chlorambucil and rituximab experienced better outcomes ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved the use of intravenous ofatumumab in combination with chlorambucil for patients with ...

Review the side-effects of Chlorambucil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Determining Prognosis in Patients With Pancreatic Endocrine Neoplasms: Can the WHO Classification System Be Simplified? Patients received alemtuzumab (30 mg three times per week, for up to 12 weeks) ...

The FDA approval of the first-line indication is based on results from a Phase III study (COMPLEMENT 1) which demonstrated statistically significant improvement in median progression-free survival ...

Patients with relapsed CLL which is refractory to chlorambucil and fludarabine should be offered combination chemotherapy [e.g. low-dose cyclophosphamide, prednisolone, vincristine and doxorubicin ...

STOCKHOLM — Final results from the phase 3 CLL11 trial confirm the superiority of the newer anti-CD20 monoclonal antibody drug obinutuzumab (Gazyva) compared to the older agent rituximab (Rituxan); ...

You have full access to this article via your institution. All subjects completed treatment, but two had significant dosing delays, one due to a mechanical ileus unrelated to therapy requiring ...

The Appraisal Committee considered evidence submitted by Roche and a review of this submission by the Evidence Review Group (ERG). Patients in CLL11 had untreated chronic lymphocytic leukaemia needing ...